MA
BNTC icon

MYDA Advisors’s Benitec Biopharma BNTC Stock Holding History

MYDA Advisors’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.4M Hold
225,000
– – 0.39% 63
2025
Q4 		$3.03M Buy
225,000
+155,000
+221% +$2.14M 0.58% 44
2025
Q3 		$982K Buy
70,000
+7,884
+13% +$101K 0.21% 96
2025
Q2 		$727K Buy
62,116
+10,116
+19% +$142K 0.13% 104
2025
Q1 		$677K Buy
52,000
+2,000
+4% +$24.2K 0.12% 104
2024
Q4 		$632K Buy
+50,000
New +$540K 0.16% 83

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MYDA Advisors's BNTC Position: Q1 2026 in Review

MYDA Advisors held its Benitec Biopharma (BNTC) position steady in Q1 2026 at 225,000 shares worth $2.4M. The position accounts for 0.39% of the portfolio, ranked #63.

MYDA Advisors first reported a position in BNTC in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.03M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • MYDA Advisors held 225,000 shares of Benitec Biopharma worth $2.4M as of Q1 2026.
  • MYDA Advisors left its Benitec Biopharma share count unchanged in Q1 2026.
  • Benitec Biopharma made up 0.39% of MYDA Advisors's portfolio in Q1 2026, its #63 holding.
  • MYDA Advisors first reported a position in Benitec Biopharma in Q4 2024 and has held it in 6 quarters since.
  • MYDA Advisors's Benitec Biopharma position peaked at $3.03M in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on MYDA Advisors's 13F filing for Q1 2026, filed 14 May 2026.